Trial Profile
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Dec 2019
Price :
$35
*
At a glance
- Drugs INCAGN 1949 (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Incyte Biosciences International
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 05 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
- 05 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.